Abstract
Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Testing for natriuretic peptide markers, such as B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP), has emerged as an important tool for the diagnosis and risk stratification of patients with HF. However, questions remain regarding the potential role for natriuretic peptides to guide therapy in patients with HF. In this Review, we address the underlying assumptions and the existing evidence supporting a natriuretic-peptide-guided approach to the outpatient management of HF.
Key Points
-
Natriuretic peptides, including B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), are useful for risk stratification in patients with heart failure
-
Several established heart failure therapies have been shown to significantly reduce the concentration of natriuretic peptides
-
Limited evidence exists that patients with higher concentrations of natriuretic peptides derive a greater benefit from established heart failure therapies than patients with lower concentrations of natriuretic peptides
-
More research is required before a natriuretic peptide-guided approach to the outpatient management of heart failure can be endorsed in all patients
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
01 April 2010
A Correction to this paper has been published: https://doi.org/10.1038/nrcardio.2010.27
References
Bonow, R. O. et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J. Am. Coll. Cardiol. 46, 1144–1178 (2005).
Krantz, M. J. et al. Influence of hospital length of stay for heart failure on quality of care. Am. J. Cardiol. 102, 1693–1697 (2008).
Albert, N. M. et al. Use of aldosterone antagonists in heart failure. JAMA 302, 1658–1665 (2009).
Braunwald, E., Harrison, D. C. & Chidsey, C. A. The heart as an endocrine organ. Am. J. Med. 36, 1–4 (1964).
Henry, J. P., Gauer, O. H. & Reeves, J. L. Evidence of the atrial location of receptors influencing urine flow. Circ. Res. 4, 85–90 (1956).
Jamieson, J. D. & Palade, G. E. Specific granules in atrial muscle cells. J. Cell Biol. 23, 151–172 (1964).
de Bold, A. J., Borenstein, H. B., Veress, A. T. & Sonnenberg, H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28, 89–94 (1981).
Sudoh, T., Kangawa, K., Minamino, N. & Matsuo, H. A new natriuretic peptide in porcine brain. Nature 332, 78–81 (1988).
Richards, A. M. et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br. Heart J. 69, 414–417 (1993).
Yasue, H. et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90, 195–203 (1994).
Magga, J., Vuolteenaho, O., Tokola, H., Marttila, M. & Ruskoaho, H. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann. Med. 30 (Suppl. 1), 39–45 (1998).
Liang, F. et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J. Am. Coll. Cardiol. 49, 1071–1078 (2007).
Tang, W. H. et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin. Biochem. 41, 210–221 (2008).
Pemberton, C. J., Johnson, M. L., Yandle, T. G. & Espiner, E. A. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 36, 355–359 (2000).
Kroll, M. H., Twomey, P. J. & Srisawasdi, P. Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. Clin. Chim. Acta 380, 197–202 (2007).
Redfield, M. M. et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. 40, 976–982 (2002).
Wang, T. J. et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol. 90, 254–258 (2002).
Wang, T. J. et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109, 594–600 (2004).
Anwaruddin, S. et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J. Am. Coll. Cardiol. 47, 91–97 (2006).
Takeishi, Y. et al. Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem. Biophys. Res. Commun. 362, 480–484 (2007).
Meirhaeghe, A. et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum. Mol. Genet. 16, 1343–1350 (2007).
Newton-Cheh, C. et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat. Genet. 41, 348–353 (2009).
Tang, W. H. et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 116, e99–e109 (2007).
Doust, J. A., Pietrzak, E., Dobson, A. & Glasziou, P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330, 625 (2005).
Anand, I. S. et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107, 1278–1283 (2003).
Bettencourt, P. et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110, 2168–2174 (2004).
Logeart, D. et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol. 43, 635–641 (2004).
Tamura, N. et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. USA 97, 4239–4244 (2000).
Oliver, P. M. et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl. Acad. Sci. USA. 94, 14730–14735 (1997).
Motwani, J. G., McAlpine, H., Kennedy, N. & Struthers, A. D. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 341, 1109–1113 (1993).
Latini, R. et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106, 2454–2458 (2002).
Tsutamoto, T. et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37, 1228–1233 (2001).
Cleland, J. G. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539–1549 (2005).
Davis, M. E. et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113, 977–985 (2006).
Stanek, B. et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J. Am. Coll. Cardiol. 38, 436–442 (2001).
Richards, A. M. et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J. Am. Coll. Cardiol. 37, 1781–1787 (2001).
Richards, A. M. et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99, 786–792 (1999).
Hartmann, F. et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110, 1780–1786 (2004).
Omland, T. et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J. Am. Coll. Cardiol. 50, 205–214 (2007).
Cleland, J. G. et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. J. Am. Coll. Cardiol. 52, 438–445 (2008).
Troughton, R. W. et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126–1130 (2000).
Jourdain, P. et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49, 1733–1739 (2007).
Shah, M. R. et al. STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure [abstract 2554]. Circulation 114, II_528 (2006).
Shah, M. R. et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am. Heart J. 150, 893–898 (2005).
Pfisterer, M. et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301, 383–392 (2009).
Richards, A. M., Lainchbury, J. G., Troughton, R. W. & Strangman, K. NT-proBNP-guided treatment for chronic heart failure: results from the Battlescarred trial [abstract 5946]. Circulation 118, S_1035–S_1036 (2008).
Eurlings, L. et al. Can pro-brain natriuretic peptide-guided therapy of heart failure improve heart failure morbidity and mortality? Main outcome of the PRIMA study [abstract 402-14]. Presented at the ACC 58th Annual Scientific Session (Orlando, USA; 29–31 March 2009).
Acknowledgements
Désirée Lie, University of California, Orange, CA is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
O'Donoghue, M., Braunwald, E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels?. Nat Rev Cardiol 7, 13–20 (2010). https://doi.org/10.1038/nrcardio.2009.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2009.197
This article is cited by
-
A Robust N-Terminal Pro-Brain Natriuretic Peptide Assay for Clinical Diagnosis of Heart Failure in Elderly Patients
Journal of Analysis and Testing (2023)
-
Clinical utility of antigen carbohydrate 125 in heart failure
Heart Failure Reviews (2014)
-
Physiological levels of A-, B- and C-type natriuretic peptide shed the endothelial glycocalyx and enhance vascular permeability
Basic Research in Cardiology (2013)
-
Device monitoring strategies in acute heart failure syndromes
Heart Failure Reviews (2011)
-
Novel Biomarkers in Acute Heart Failure
Current Heart Failure Reports (2011)